摘要
目的本研究探讨着色性干皮病基因组C(xeroderma pigmentosum group C,XPC)基因的遗传变异对接受奥沙利铂为基础辅助化疗的Ⅲ期结直肠癌(colorectal cancer,CRC)患者的预后及安全性的影响。方法研究纳入186例接受手术切除治疗且术后接受奥沙利铂方案辅助化疗的Ⅲ期CRC患者。此外,收集患者的外周血生物学标本进行XPC基因遗传变异分析。XPC基因多态性和无疾病生存期的关联分析采用Kaplan⁃Meier方法进行,通过卡方检验探讨基因型和不良反应的相关性。结果186例患者的中位无疾病生存期(disease⁃free survival,DFS)为4.3年,中位总生存期(overall survival,OS)为5.5年。遗传变异分析结果提示位于XPC基因编码区的rs2228001位点与预后及安全性相关。预后分析结果表明TT和TG/GG基因型患者的中位DFS分别为3.8年和5.0年,差异有统计学意义(P=0.012)。两种基因型患者的中位OS分别为5.0年和5.7年,差异有统计学意义(P=0.021)。rs2228001位点基因型和不良反应分析结果表明TG/GG基因型患者相对于TT基因型患者伴随了相对较高的神经毒性发生率(72.9%vs.55.4%,P=0.014)。结论XPC基因rs2228001位点可以作为预测接受奥沙利铂为基础辅助化疗的Ⅲ期CRC患者预后及神经毒性的生物标志物。
Objective To explore the influence of xeroderma pigmentosum group C(XPC)genetic variation on the prognosis and safety of stageⅢpatients with colorectal cancer(CRC)receiving oxaliplatin⁃based adjuvant chemotherapy.Methods A total of 186 patients with CRC who were treated with surgical resection and oxaliplatin⁃based adjuvant chemotherapy were included in this study.Peripheral blood specimens of the patients were collected for genetic variation analysis of XPC gene.The univariate analysis between XPC genetic variation and prognosis was performed by Kaplan⁃Meier survival analysis.The correlation analysis between genotype and adverse reactions was analyzed using chi⁃square test.Results The median disease⁃free survival(DFS)and overall survival(OS)of the 186 patients with CRC was 4.3 years and 5.5 years,respectively.Rs2228001 was of clinical significance with prognosis and safety.Prognostic analysis demonstrated that the median DFS of patients with TT genotype and TG/GG genotype was 3.8 and 5.0 years respectively,which was statistically significant(P=0.012).Fur⁃thermore,the median OS of the two genotypes were 5.0 and 5.7 years respectively,which was marginal statistical significance(P=0.021).The association analysis between rs2228001 genotype and adverse reaction suggested that patients with TG/GG genotype were associated with a relatively higher incidence of neurotoxicity than that with TT genotype(72.9%vs.55.4%,P=0.014).Conclusion XCP gene rs2228001 polymorphism could be used as a biomarker for prognosis and neurotoxicity evaluation of patients with CRC who received oxaliplatin⁃based adjuvant chemotherapy.
作者
郑凯
张天可
付文政
ZHENG Kai;ZHANG Tianke;FU Wenzheng(Department of Anus and Intestine,Tianjin People′s Hospital,Tianjin 300191,China)
出处
《实用医学杂志》
CAS
北大核心
2021年第10期1301-1306,共6页
The Journal of Practical Medicine
基金
天津市卫计委科技基金(编号:No.2014KZ053)。
